MTRX31 / MitoRx Therap - LARVOL DELTA

Myo-004 Induces Body-Weight Loss in DIO at Thermoneutrality by Switching Metabolism from Fat to Carbohydrate Oxidation (ADA 2026) - "Our mitochondrial-targeted small molecules provide an alternative mode-of-action to modulate metabolism to combat obesity. Male C57BL/6J mice fed high-fat diet (60%) or standard chow from week 6 of age for 15 weeks were dosed with Myo-004 (1 and 5 mg/kg; s.c. TIW), tirzepatide (5 nmol/kg, s.c. QD), bimagrumab (20 mg/kg, s.c, QW) or combinations for 8 weeks (n=10). Altogether, Myo-004 demonstrates potent anti-obesogenic properties that are long lasting in the DIO model at thermoneutrality. Bodyweight loss is associated with strong reduction in fat while preserving lean mass as well as grip-strength suggesting muscle function preservation. Improvement in metabolic capacity (increased RER) and a switch between fat and carbohydrates oxidation support a differentiated mode-of-action from incretins or uncouplers thus providing alternative solutions for individuals living with obesity or for maintenance therapies after incretins therapy cessation."

Metabolic Disorders • Obesity

Characterisation of Myo4 in the murine diet-induced obesity model: a first-in-class anti-obesogenic muscle-preserving small molecule metabolic modulator. (EASD 2025) - "Clinical trials such as STEP1, STEP4, and SUSTAIN8 with semaglutide showed lean mass accounted for 40% of weight loss, with similar results observed with liraglutide (SCALE), tirzepatide (SURMOUNT-1), and dulaglutide (AWARD-11)... Myo4 is a novel anti-obesogenic and muscle-preserving therapeutic, usable as monotherapy for obesity requiring weight loss with muscle preservation, or in combination with GLP-1RA to prevent loss of SkM mass/function."

Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

New data backs Myo4 for obesity treatment (Drug Target Review) - "MitoRx Therapeutics Limited (MitoRx), a platform biotech company pioneering mitochondrial-targeted persulfide modifiers, has announced new preclinical data demonstrating the efficacy of its small molecule drug candidate, Myo4, in treating obesity. The results were presented in a poster session at the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago....The study highlights Myo4’s ability to restore insulin sensitivity in a widely used murine diet-induced obesity (DIO) model, building on earlier findings that it reduces fat while preserving muscle and bone health."

Preclinical • Obesity